https://www.pharmaradar360.com/article/37dc74d9712b0dcdPharma Surgeen2026-06-04T11:03:13.000ZStopping Cancer Before It Starts in Lynch Syndromehttps://www.pharmaradar360.com/article/f73f0b609f6b3d44Pharma Surgeen2026-06-04T10:56:55.000ZTaking control: Inspiring others to beat rare diseaseshttps://www.pharmaradar360.com/article/ecc4d4618204356ePharma Surgeen2026-06-04T10:54:56.000ZPaul van Geest presents Erasmus University research to Pope Leo XIV in Romehttps://www.pharmaradar360.com/article/fcd8ecf60054a397Pharma Surgeen2026-06-04T10:45:50.000ZMedicine levy makes the UK un-investable, say pharma leadershttps://www.pharmaradar360.com/article/6e1c6e168dd16e4fPharma Surgeen2026-06-04T10:34:03.000ZTeviot joins Pride Edinburgh celebrationshttps://www.pharmaradar360.com/article/08fbad1366deb8d4Pharma Surgeen2026-06-04T10:32:18.000ZCome on England! Fans urged to register their organ donation decision during the World Cuphttps://www.pharmaradar360.com/article/8a35d4e112d8bb5fPharma Surgeen2026-06-04T10:30:04.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/adb7ed42160da19fPharma Surgeen2026-06-04T10:19:36.000ZNovartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearshttps://www.pharmaradar360.com/article/57e56d16f5bf0f31Pharma Surgeen2026-06-04T10:19:17.000Z医薬品・医療機器等安全性情報 No.429（厚生労働省）https://www.pharmaradar360.com/article/227fce387363a048Pharma Surgeen2026-06-04T10:01:58.000ZNew wave of harm reduction specialists graduate as life-saving programme expands across Greater Glasgow and Clydehttps://www.pharmaradar360.com/article/1a2290fc8ef81437Pharma Surgeen2026-06-04T10:00:30.000ZClass 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27https://www.pharmaradar360.com/article/703172fdb4940001Pharma Surgeen2026-06-04T10:00:00.000ZWhat’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANAhttps://www.pharmaradar360.com/article/58f0e186d4ab3e4aPharma Surgeen2026-06-04T09:52:07.000ZUniversité Paris Cité, the Île-de-France Region, the City of Paris and LVMH lay the foundation stone of the Interdisciplinary Institute for Women’s Health (iWISH)https://www.pharmaradar360.com/article/2be104594c2f66c9Pharma Surgeen2026-06-04T09:51:02.000ZEMA and AMA collaborate on Ebola trials amid public health emergencyhttps://www.pharmaradar360.com/article/b54fa34c5af76511Pharma Surgeen2026-06-04T09:47:25.000ZSoftware documentation audits after QMSR | Greenlight Guruhttps://www.pharmaradar360.com/article/b18931cfcc532fcfPharma Surgeen2026-06-04T09:44:36.000ZEli Lilly continues genetic medicine push with $1.9bn Ascidian partnershiphttps://www.pharmaradar360.com/article/0fe31bf714e3d8f8Pharma Surgeen2026-06-04T09:43:12.000ZInternationalisation at home: why get started?https://www.pharmaradar360.com/article/62a8b14065a54d5aPharma Surgeen2026-06-04T09:32:07.000ZMassive Bio and Optellum partner on early NSCLC detection and trialshttps://www.pharmaradar360.com/article/3e11cadaa665c564Pharma Surgeen2026-06-04T09:28:43.000ZCellares and TScan to assess automated manufacturing of TSC-101 therapyhttps://www.pharmaradar360.com/article/63f1ccef4c60c5ecPharma Surgeen2026-06-04T09:02:49.000ZCardiopatie: il convegno in Humanitashttps://www.pharmaradar360.com/article/fab01b1e5057dfa6Pharma Surgeen2026-06-04T09:00:11.000Z医学イノベーション研究所（SiRIUS）の小林 天美講師が「第5回羽ばたく女性研究者賞（マリア・スクウォドフスカ＝キュリー賞）」の奨励賞を受賞しましたhttps://www.pharmaradar360.com/article/5980ff1cb8d2604fPharma Surgeen2026-06-04T08:56:00.000ZDengue Vaccine Shows Favourable Safety Profile in Travellers from Non-Endemic Regionshttps://www.pharmaradar360.com/article/cd020fc6eea968b6Pharma Surgeen2026-06-04T08:49:39.000ZObésité : les disparités s'accentuent entre pays développés et en développementhttps://www.pharmaradar360.com/article/9ea21cb28e6ea8a1Pharma Surgeen2026-06-04T08:31:00.000ZMore premature births due to the heat. What can we do?https://www.pharmaradar360.com/article/f16dc26327f136ddPharma Surgeen2026-06-04T08:28:55.000ZAME และ AME Group ได้รับตราสัญลักษณ์มาตรฐานไมซ์ในงาน MICE Standards Day 2026https://www.pharmaradar360.com/article/b5f3da99ff8ceb35Pharma Surgeen2026-06-04T08:27:01.000ZJ&J’s nipocalimab meets primary endpoint in Phase II JASMINE studyhttps://www.pharmaradar360.com/article/af510242741fcf1fPharma Surgeen2026-06-04T08:24:59.000ZLa cardiologie des HUS rayonne à l’internationalhttps://www.pharmaradar360.com/article/a0c26a07d3f47279Pharma Surgeen2026-06-04T08:21:36.000ZRegeneron and CytomX extend cancer therapy partnership to $4bn dealhttps://www.pharmaradar360.com/article/37cffcefd2433d89Pharma Surgeen2026-06-04T08:09:39.000ZPrivate equity firm invests in radiology services provider RadX Inc.https://www.pharmaradar360.com/article/25eb7532fb46984dPharma Surgeen2026-06-04T08:00:01.000ZRadNet seeks to secure $200M term loan to fuel expansionhttps://www.pharmaradar360.com/article/7b8ef20995be99b4Pharma Surgeen2026-06-04T07:46:22.000ZPrivate equity firm acquires Heritage Imaginghttps://www.pharmaradar360.com/article/f5f5a0d988987c8aPharma Surgeen2026-06-04T07:43:38.000ZLe Leem dévoile son Plan Compétences Biotech 2030 à l’occasion de la JNBB 2026https://www.pharmaradar360.com/article/a5d6522a529d437fPharma Surgeen2026-06-04T07:30:45.000ZLa AEMPS refuerza el control del mercado de productos cosméticos con cerca de 2.000 actuaciones en 2025https://www.pharmaradar360.com/article/13a8c340544bd476Pharma Surgeen2026-06-04T07:00:00.000Z‘What if that could be me?’https://www.pharmaradar360.com/article/f2ed0736aab25a8aPharma Surgeen2026-06-04T07:00:00.000ZTeresa Macarulla and Tian Tian lead the new IDIBAPS research group 'Translational oncology in upper gastrointestinal cancers'https://www.pharmaradar360.com/article/592b4d89a1e4f65dPharma Surgeen2026-06-04T06:58:00.000ZThree to join Interim Chancellor Davies at June 8 forumhttps://www.pharmaradar360.com/article/ed2696c934991dd5Pharma Surgeen2026-06-04T06:56:00.000ZHealing Arts Program launches first staff art exhibitionhttps://www.pharmaradar360.com/article/bd554083d96a1e69Pharma Surgeen2026-06-04T06:54:00.000ZNicki Simmons retires from CAHP after 30 yearshttps://www.pharmaradar360.com/article/d7b04de0e54cbf8aPharma Surgeen2026-06-04T06:50:00.000ZBox verification system changing at 6 p.m. todayhttps://www.pharmaradar360.com/article/a7e3441cfcfa14d3Pharma Surgeen2026-06-04T06:35:50.000ZOCULOTECT 50 mg/ml COLIRIO EN SOLUCION , 1 frasco de 10 ml (NR: 61982, CN: 755215)https://www.pharmaradar360.com/article/ed344081aa5a4570Pharma Surgeen2026-06-04T06:33:23.000ZVGR växlar upp i Almedalen – tre publika panelsamtalhttps://www.pharmaradar360.com/article/484e18661669d40cPharma Surgeen2026-06-04T06:31:55.000ZEvents in Junehttps://www.pharmaradar360.com/article/dea2964dd05f530dPharma Surgeen2026-06-04T06:30:55.000ZJohn Browett named chair of NHS online hospital trusthttps://www.pharmaradar360.com/article/c660bd4ae358f0b1Pharma Surgeen2026-06-04T06:24:22.000ZBispecific and multi-specific antibody development journey at WuXi Biologicshttps://www.pharmaradar360.com/article/ee8946d67756410aPharma Surgeen2026-06-04T06:00:00.000ZLe mystère des poissons devenus aveugleshttps://www.pharmaradar360.com/article/bbfa8b4f26c30c53Pharma Surgeen2026-06-04T05:30:22.000ZCancer’s favorite escape trick may actually make it easier to killhttps://www.pharmaradar360.com/article/69d3c0547ad07b09Pharma Surgeen2026-06-04T05:01:40.000ZFederation Plus Fine Tuning: The Push for Federated Learning Models Continueshttps://www.pharmaradar360.com/article/02942e36485a469bPharma Surgeen2026-06-04T05:00:00.000ZNorthwest Arkansas Pathology Associates adopts Techcyte Fusion® AP to enable remote pathology and address workforce shortageshttps://www.pharmaradar360.com/article/fa94eb9a008da98bPharma Surgeen2026-06-04T04:16:06.000Z「美味しいサプリ」をグミで。少量生産を実現する新ソリューション「グミ ミニ・プラント」販売開始https://www.pharmaradar360.com/article/f970841bb7f6b396Pharma Surgeen2026-06-04T04:13:00.000ZAlnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneerhttps://www.pharmaradar360.com/article/6811cfe4e486ffc8Pharma Surgeen2026-06-04T03:15:23.000Z【日本医学会】第10回研究倫理教育研修会「医学・医療と共に進化する研究倫理」収録映像公開のご案内https://www.pharmaradar360.com/article/e4c14047ed2b745bPharma Surgeen2026-06-04T03:00:00.000Z[IBENTO][IBENTO]Report on the PMDA-ATC 10th Anniversary Ceremony has been posted.https://www.pharmaradar360.com/article/5fa195e70e962aa6Pharma Surgeen2026-06-04T03:00:00.000Z[SHINSA]English Translation of Review Report: Doptelet (Partial Change Approval)https://www.pharmaradar360.com/article/eff3a58e129481fbPharma Surgeen2026-06-04T03:00:00.000Z[SHINSA]English-language Early Considerations 'Considerations for the General Toxicity Evaluation of Monoclonal Antibodies （Early Consideration）' has been published.https://www.pharmaradar360.com/article/c92ae3558119cc6fPharma Surgeen2026-06-04T02:00:00.000ZPremio Innovazione Digitale in Sanità 2026, anche il Policlinico di Milano tra i vincitorihttps://www.pharmaradar360.com/article/9ca521d4d334e8ebPharma Surgeen2026-06-04T01:57:47.000Z抗悪性腫瘍経口黄体ホルモン製剤「ヒスロンH錠200mg」の限定出荷に関するお詫びとお知らせ_第2報（協和キリン株式会社）https://www.pharmaradar360.com/article/6ceb532d6c57218aPharma Surgeen2026-06-04T00:54:30.000Z市民公開講座「難聴と誤嚥」を開催しましたhttps://www.pharmaradar360.com/article/36e66203c0d2a791Pharma Surgeen2026-06-04T00:00:00.000ZIntrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trialhttps://www.pharmaradar360.com/article/534bb9b520c0a116Pharma Surgeen2026-06-04T00:00:00.000ZBacterial engineering for cancer therapyhttps://www.pharmaradar360.com/article/a717be9aa7429e50Pharma Surgeen2026-06-04T00:00:00.000ZAberrant tau accumulation caused by MAPT mutations induces early pathological changes in axonal transport that are rescued by p38α inhibitionhttps://www.pharmaradar360.com/article/ae48c340949a8299Pharma Surgeen2026-06-04T00:00:00.000ZAAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trialhttps://www.pharmaradar360.com/article/da4f7fa27ece4773Pharma Surgeen2026-06-04T00:00:00.000ZSpinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trialhttps://www.pharmaradar360.com/article/b90b9ea2c7cd356bPharma Surgeen2026-06-04T00:00:00.000ZA socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trialhttps://www.pharmaradar360.com/article/8489ad36c945e820Pharma Surgeen2026-06-04T00:00:00.000ZHuman microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resiliencehttps://www.pharmaradar360.com/article/37f9e7c70e774b3bPharma Surgeen2026-06-04T00:00:00.000ZMarked for destructionhttps://www.pharmaradar360.com/article/912837976820fabbPharma Surgeen2026-06-04T00:00:00.000ZThis mysterious lung disease affects millions of people – a drug tested in mice shows promisehttps://www.pharmaradar360.com/article/1fdbc792758fb9faPharma Surgeen2026-06-04T00:00:00.000ZWhat’s behind China’s historically high counts of corresponding authors?https://www.pharmaradar360.com/article/b0f48c578b262c49Pharma Surgeen2026-06-04T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/c634d98bdbffaf52Pharma Surgeen2026-06-04T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/11ec0a079cd440cbPharma Surgeen2026-06-04T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/d5efaf9fe5bd22b4Pharma Surgeen2026-06-04T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/88431901baa693d1Pharma Surgeen2026-06-04T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/261a7217f8eea200Pharma Surgeen2026-06-04T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/ee615bdb3db06e59Pharma Surgeen2026-06-04T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/e166f44fefd1685cPharma Surgeen2026-06-04T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/7b04c69dba7a900fPharma Surgeen2026-06-04T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/c6b81c05e314013cPharma Surgeen2026-06-04T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/aee3bb000af1b66dPharma Surgeen2026-06-04T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/1c354a0846de22a4Pharma Surgeen2026-06-04T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/7c9c02f47ba3c14fPharma Surgeen2026-06-04T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/adde48b4e4f37ae1Pharma Surgeen2026-06-04T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/413458cfb2d7ace7Pharma Surgeen2026-06-04T00:00:00.000ZCER under MEDDEV 2.7/1 Rev. 4 and EU MDR | Greenlight Guruhttps://www.pharmaradar360.com/article/1de2f83cdf501d33Pharma Surgeen2026-06-04T00:00:00.000ZGH Research Announces Publication of Phase 2a Postpartum Depression Resultshttps://www.pharmaradar360.com/article/3c926190f334b9a9Pharma Surgeen2026-06-04T00:00:00.000ZRiskgränsvärden för njursjukdom bekräftas genom mer exakta mätningarhttps://www.pharmaradar360.com/article/090496c2262ea14dPharma Surgeen2026-06-04T00:00:00.000ZÖvervakning av hjärtrytm i mobilen kan spara vårdresurserhttps://www.pharmaradar360.com/article/6ee97200092b2a29Pharma Surgeen2026-06-04T00:00:00.000ZFilantropiskt stöd av familjen Savén stärker forskning om kolorektalcancerhttps://www.pharmaradar360.com/article/831e6395a4574996Pharma Surgeen2026-06-03T22:57:08.000ZFT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseaseshttps://www.pharmaradar360.com/article/b2c51a7c191a231ePharma Surgeen2026-06-03T22:55:21.000ZSafety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Dischargehttps://www.pharmaradar360.com/article/556016a12c4bc8b5Pharma Surgeen2026-06-03T21:06:21.000ZSNMMI unveils 2026 Image of the Yearhttps://www.pharmaradar360.com/article/c52fe069c74c309aPharma Surgeen2026-06-03T20:00:07.000ZPharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burdenhttps://www.pharmaradar360.com/article/de0e7a866048034fPharma Surgeen2026-06-03T19:42:21.000ZHuman Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstreamhttps://www.pharmaradar360.com/article/7a286b7bcf7cd849Pharma Surgeen2026-06-03T19:19:22.000ZMoving Trials Forward: Inside the Merck and WCG Partnership that Unblocks Bottlenecks and Empowers Siteshttps://www.pharmaradar360.com/article/c10a72d4abd3660dPharma Surgeen2026-06-03T19:07:50.000ZSmall Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+https://www.pharmaradar360.com/article/00fae60a0b595d9ePharma Surgeen2026-06-03T19:00:07.000ZCellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancieshttps://www.pharmaradar360.com/article/086e63dd1417a342Pharma Surgeen2026-06-03T18:54:24.000ZNew Antibiotic, Manikomycin, Acts on Novel Ribosomal Targethttps://www.pharmaradar360.com/article/df84f2a87bc6fa61Pharma Surgeen2026-06-03T18:47:32.000ZAI triage tool slashes breast cancer screening workloads by 77%https://www.pharmaradar360.com/article/2422784bc7ebcc25Pharma Surgeen2026-06-03T18:30:49.000ZNew nursing hireshttps://www.pharmaradar360.com/article/bc2cc2eed1cbc203Pharma Surgeen2026-06-03T18:09:38.000ZNORD Joins Coalition of 48 Patient Advocacy Organizations Expressing Concerns Over Coverage Loss Under Final CMS Medicaid Work Requirementhttps://www.pharmaradar360.com/article/0f43f51f45e01df8Pharma Surgeen2026-06-03T17:47:40.000ZAn End-to-End Approach to Specialty Patient Serviceshttps://www.pharmaradar360.com/article/ccc9831befd6d890Pharma Surgeen2026-06-03T17:36:27.000ZDermacyd lança campanha sobre intimidade e relaçõeshttps://www.pharmaradar360.com/article/115c1c66cc7aa5d1Pharma Surgeen2026-06-03T17:30:18.000ZGrupo EMS anuncia rebranding, apresenta nova arquitetura de marcas e se posiciona como potência do setor farmacêutico no Brasilhttps://www.pharmaradar360.com/article/2abc1edd69fcba11Pharma Surgeen2026-06-03T17:21:57.000ZFocus apps are failing neurodivergent minds, new research findshttps://www.pharmaradar360.com/article/842eb68a03c4557bPharma Surgeen2026-06-03T17:07:53.000ZTar Heel researchers share their work with chancellor on the coasthttps://www.pharmaradar360.com/article/93446856b3088314Pharma Surgeen2026-06-03T17:03:24.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/dfb046437b00af6fPharma Surgeen2026-06-03T17:00:00.000ZDigital Collaboration in the Pharmaceutical Cold Chain: How CSafe Connects Data, Systems, and Stakeholdershttps://www.pharmaradar360.com/article/5dee9f487593548bPharma Surgeen2026-06-03T16:59:42.000Z33° Jornadas de Jóvenes Investigadores en Brasil (AUGM)https://www.pharmaradar360.com/article/5cc46fd39bdd3da6Pharma Surgeen2026-06-03T16:59:40.000ZIntelligence for the decisions that matter mosthttps://www.pharmaradar360.com/article/dbb248c0eba57c00Pharma Surgeen2026-06-03T16:59:20.000ZSAHPRA strengthens industry collaboration to improve access to safe medicineshttps://www.pharmaradar360.com/article/d4612f921be7372aPharma Surgeen2026-06-03T16:53:00.000ZCommonwealth Fund: 21% of adults experienced a coverage denial in the past yearhttps://www.pharmaradar360.com/article/a3b1817ef172d077Pharma Surgeen2026-06-03T16:40:06.000Z8 new topics added in latest ACR Appropriateness Criteria updatehttps://www.pharmaradar360.com/article/e2598798579b7c6aPharma Surgeen2026-06-03T16:39:26.000ZHow to value a biotechhttps://www.pharmaradar360.com/article/62ab48e8e82c55f7Pharma Surgeen2026-06-03T16:30:59.000ZFramework for Review of Clinical Research Involving AI: Advancing Ethical Oversight in Clinical Researchhttps://www.pharmaradar360.com/article/b64b030390c11dffPharma Surgeen2026-06-03T16:26:16.000ZEli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Reporthttps://www.pharmaradar360.com/article/3c0ef02b9be036c1Pharma Surgeen2026-06-03T16:07:10.000ZUFRJ instala Gabinete de Crise para atuação em situações de violência urbanahttps://www.pharmaradar360.com/article/771a20c121070ac9Pharma Surgeen2026-06-03T16:07:00.000ZNew FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledgehttps://www.pharmaradar360.com/article/d1fccbc31ee53b01Pharma Surgeen2026-06-03T16:00:52.000ZBioproduction Pivots from Centralized to Regional Supporthttps://www.pharmaradar360.com/article/8bacc24fcc3604e8Pharma Surgeen2026-06-03T16:00:51.000ZGentler Cell Separation Methods Gain Momentumhttps://www.pharmaradar360.com/article/d32fab7467d1c226Pharma Surgeen2026-06-03T16:00:46.000ZWeb App Helps Flag Antibodies Where Manufacturability Might Be an Issuehttps://www.pharmaradar360.com/article/f87b1a3d8a7774ebPharma Surgeen2026-06-03T16:00:40.000ZNIIMBL to Support Vector Production and AI-Ready Training Projectshttps://www.pharmaradar360.com/article/21f5cbcf95a9b9d1Pharma Surgeen2026-06-03T16:00:00.000ZRubio reopening door with Gavihttps://www.pharmaradar360.com/article/f02564f6604ae6b7Pharma Surgeen2026-06-03T15:50:24.000ZVisita de la Universidad china de Yanshan para fortalecer la cooperación internacionalhttps://www.pharmaradar360.com/article/0006887a926d1ffcPharma Surgeen2026-06-03T15:49:21.000ZTauber recorrió las obras del edificio Anexo de Derechohttps://www.pharmaradar360.com/article/d265f45ed41d332dPharma Surgeen2026-06-03T15:48:45.000ZTauber: “La Universidad tiene que estar donde más se la necesita”https://www.pharmaradar360.com/article/24b03665804f3dd9Pharma Surgeen2026-06-03T15:44:55.000ZOver 8,600 class of 2026 members will attend commencement ceremonies this monthhttps://www.pharmaradar360.com/article/e953c0e5029c58d7Pharma Surgeen2026-06-03T15:41:31.000ZCellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Networkhttps://www.pharmaradar360.com/article/b2975223f1df84dcPharma Surgeen2026-06-03T15:34:12.000ZNovartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientshttps://www.pharmaradar360.com/article/857193c1a5018856Pharma Surgeen2026-06-03T15:33:32.000ZISSUE NO. 49 — Nonclinical Toxicology Studieshttps://www.pharmaradar360.com/article/75f73b3f3f674645Pharma Surgeen2026-06-03T15:28:54.000ZImmune Cell Phenotyping: Cell Surface Architecture Informs Disease Biologyhttps://www.pharmaradar360.com/article/e24be1e61b6dddd2Pharma Surgeen2026-06-03T15:21:54.000ZSaif Khairat to serve as chief AI officerhttps://www.pharmaradar360.com/article/7abbccb9733b4638Pharma Surgeen2026-06-03T15:16:21.000ZImmune Response Activated by RNA Splicing Opens Targeted Therapieshttps://www.pharmaradar360.com/article/206a08278d7c5fcePharma Surgeen2026-06-03T15:03:34.000ZHighlights of ASCO 2026: how is cancer care evolving?https://www.pharmaradar360.com/article/c12101ea3c1e351ePharma Surgeen2026-06-03T15:02:37.000ZLonza Advances Integrated DNA to IND Programs Through Acceleration, De Risking, and Innovationhttps://www.pharmaradar360.com/article/81b9b52084efdb29Pharma Surgeen2026-06-03T15:00:12.000ZAlabama man defies early prognosis following life-threatening accidenthttps://www.pharmaradar360.com/article/f84b5425ff26f3fePharma Surgeen2026-06-03T15:00:01.000Z“Preventing a cancer from ever developing is one of the greatest contributions we can make” – Raymond DuBois wins Outstanding Achievement in Cancer Prevention Research Awardhttps://www.pharmaradar360.com/article/202b4391134adbc2Pharma Surgeen2026-06-03T14:58:11.000ZThe American Diabetes Association’s Statement on the OMB’s Financial Assistance Proposed Rulehttps://www.pharmaradar360.com/article/b8156b76ab742edcPharma Surgeen2026-06-03T14:50:56.000ZStatement from the American Diabetes Association on the CMS’s Medicaid Work Requirements Interim Final Rulehttps://www.pharmaradar360.com/article/69d340ba2a4d7ea3Pharma Surgeen2026-06-03T14:50:31.000ZViral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliancehttps://www.pharmaradar360.com/article/93f940e97a2bdc8dPharma Surgeen2026-06-03T14:41:00.000ZLilly, Boehringer to slash at least $1B each from planned investments in Germanyhttps://www.pharmaradar360.com/article/ce979ce185fe5be0Pharma Surgeen2026-06-03T14:41:00.000ZLilly, Boehringer to slash at least $1B each from planned investments in Germanyhttps://www.pharmaradar360.com/article/e2791e300c00141fPharma Surgeen2026-06-03T14:34:00.000ZPresbyterian Healthcare Services to discontinue MA plans in 2027, cut 150 jobshttps://www.pharmaradar360.com/article/9ee997373415d1cfPharma Surgeen2026-06-03T14:04:58.000ZPopular GLP-1 weight-loss drugs linked to lower risks of addiction and overdosehttps://www.pharmaradar360.com/article/5ee500d53c0fc0b1Pharma Surgeen2026-06-03T14:00:00.000ZWill the widespread use of large language models in scientific writing undermine scientists’ critical thinking?https://www.pharmaradar360.com/article/e4477c55d7822b9fPharma Surgeen2026-06-03T13:55:16.000ZNanomedicine: Italian research to improve the treatment of brain tumorshttps://www.pharmaradar360.com/article/c6ef58ee7ddf80e9Pharma Surgeen2026-06-03T13:41:27.000ZMore Insights from ACRP 2026: Can Sites, Sponsors, and CROs All Just Get Along?https://www.pharmaradar360.com/article/73bab01765328dd9Pharma Surgeen2026-06-03T13:37:41.000ZUS lawmakers reveal policy to curb collaboration with Chinese biotechhttps://www.pharmaradar360.com/article/00d7c5ebba2d2cdaPharma Surgeen2026-06-03T13:34:53.000ZAscidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editorshttps://www.pharmaradar360.com/article/db93f4dd69f0b3afPharma Surgeen2026-06-03T13:27:40.000ZThis new diabetes pill burns fat without the downsides of Ozempichttps://www.pharmaradar360.com/article/b3e159da392aff61Pharma Surgeen2026-06-03T13:25:58.000ZNew type of inhibitor could help tackle resistance against ‘last-resort’ antibioticshttps://www.pharmaradar360.com/article/87871d2cbb27e38fPharma Surgeen2026-06-03T13:20:13.000ZSPCG – Key Messages – 21 May 2026https://www.pharmaradar360.com/article/0c95d483966124baPharma Surgeen2026-06-03T13:00:00.000Z硬式野球部が京都市市民憲章推進者 区長表彰を受賞https://www.pharmaradar360.com/article/b3588ed11a65db8aPharma Surgeen2026-06-03T13:00:00.000ZCSPC’s SYS-6063 gains Chinese trial clearance for SLEhttps://www.pharmaradar360.com/article/7247b8df1efd13a8Pharma Surgeen2026-06-03T12:56:10.000ZMöglicher Biomarker für personalisierte Leukämie-Therapie identifizierthttps://www.pharmaradar360.com/article/cf0123ab3fd01e7ePharma Surgeen2026-06-03T12:56:02.000ZThe Faculty of Medicine at Université Paris Cité is launching its first international summer schools, showcasing Paris as a hub for innovation in healthcarehttps://www.pharmaradar360.com/article/fbc224b2067796e5Pharma Surgeen2026-06-03T12:49:00.000ZJune 12, 13 and 14: three days of student engagement for an ecological and socially responsible societyhttps://www.pharmaradar360.com/article/390181e83d8bcbe9Pharma Surgeen2026-06-03T12:47:47.000ZScience as Part of a Negotiation Processhttps://www.pharmaradar360.com/article/632e0257fc15b4c1Pharma Surgeen2026-06-03T12:43:52.000ZSpołeczności lokalnehttps://www.pharmaradar360.com/article/4713313f7b9aa29fPharma Surgeen2026-06-03T12:43:51.000ZAtrakcyjność Delpharmhttps://www.pharmaradar360.com/article/db58335ceb486c88Pharma Surgeen2026-06-03T12:43:50.000ZZaangażowanie pracownikówhttps://www.pharmaradar360.com/article/d38e9005a624f9a4Pharma Surgeen2026-06-03T12:43:48.000ZDelpharm Academyhttps://www.pharmaradar360.com/article/fea894f4d72ce405Pharma Surgeen2026-06-03T12:43:47.000ZRozwój pracownikówhttps://www.pharmaradar360.com/article/576a940d9bf65063Pharma Surgeen2026-06-03T12:43:46.000ZZdrowie i bezpieczeństwohttps://www.pharmaradar360.com/article/9b1b02fd2c5111dbPharma Surgeen2026-06-03T12:43:44.000ZW Delpharm pracownicy stanowią największe bogactwo Grupy.https://www.pharmaradar360.com/article/c81b7209a8e256d8Pharma Surgeen2026-06-03T12:43:40.000ZKarta etyczna – Kodeks postępowaniahttps://www.pharmaradar360.com/article/8a1afe2dc42d95dcPharma Surgeen2026-06-03T12:43:39.000ZEtyka, uczciwość i zapobieganie korupcjihttps://www.pharmaradar360.com/article/7eb6a3bb73bae8c4Pharma Surgeen2026-06-03T12:43:37.000ZPriorytet dla partnerów lokalnych i europejskichhttps://www.pharmaradar360.com/article/2cf3e91ee640e788Pharma Surgeen2026-06-03T12:43:36.000ZPolityka odpowiedzialnych zakupówhttps://www.pharmaradar360.com/article/40919b8c714d107aPharma Surgeen2026-06-03T12:43:34.000ZNasze zaangażowanie na rzecz odpowiedzialnego łańcucha dostawhttps://www.pharmaradar360.com/article/8602070d8d9a01c2Pharma Surgeen2026-06-03T12:43:29.000ZNasza polityka jakościhttps://www.pharmaradar360.com/article/6253b3e5f405d25aPharma Surgeen2026-06-03T12:43:27.000ZAkredytacje i certyfikatyhttps://www.pharmaradar360.com/article/e8412da37cb7e751Pharma Surgeen2026-06-03T12:43:26.000ZZaangażowanie w jakość wpisane w nasze DNAhttps://www.pharmaradar360.com/article/ea11e1d7d3735117Pharma Surgeen2026-06-03T12:43:25.000ZKultura jakościhttps://www.pharmaradar360.com/article/68230856bc2c7cebPharma Surgeen2026-06-03T12:43:20.000ZNasze zaangażowanie na rzecz przyszłości niskoemisyjnejhttps://www.pharmaradar360.com/article/34382d2cdbb4d97fPharma Surgeen2026-06-03T12:43:19.000ZCele środowiskowehttps://www.pharmaradar360.com/article/faa55c39c48970e2Pharma Surgeen2026-06-03T12:43:17.000ZWyniki w zakresie ochrony środowiskahttps://www.pharmaradar360.com/article/f7fa31a67b4f7806Pharma Surgeen2026-06-03T12:43:08.000ZOdpady i gospodarka o obiegu zamkniętymhttps://www.pharmaradar360.com/article/7c25fc5901abb5d5Pharma Surgeen2026-06-03T12:38:40.000ZThe scientists behind the data: investing in Europe’s data stewardship workforcehttps://www.pharmaradar360.com/article/6d5aed4a458642eePharma Surgeen2026-06-03T12:30:47.000ZHaus Buhl to be Reopened as Venue for Events and Conferenceshttps://www.pharmaradar360.com/article/44cb54626009e03fPharma Surgeen2026-06-03T12:30:26.000ZAlmost 33,000 Bedfordshire patients had data stolen in cyber attackhttps://www.pharmaradar360.com/article/17db4f171183c648Pharma Surgeen2026-06-03T12:30:12.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/45205a482afe9837Pharma Surgeen2026-06-03T12:23:19.000ZClimate is the real game changerhttps://www.pharmaradar360.com/article/70928575a99eb897Pharma Surgeen2026-06-03T12:23:01.000ZRegulatory Pathways by Region―A Comparative Tablehttps://www.pharmaradar360.com/article/743d03eb3987947dPharma Surgeen2026-06-03T12:16:56.000ZScientists reverse anxiety by fixing a tiny brain circuithttps://www.pharmaradar360.com/article/7c6afa04891947b5Pharma Surgeen2026-06-03T12:16:11.000ZLa mastectomie endoscopique poursuit son essorhttps://www.pharmaradar360.com/article/f973ceb363631ba7Pharma Surgeen2026-06-03T12:03:26.000ZUpdate for LEGEhttps://www.pharmaradar360.com/article/94ab7ad7c85b7b4aPharma Surgeen2026-06-03T11:56:40.000ZLa AEMPS publica el sexto informe de seguimiento del Linfoma Anaplásico de Células Grandes (LACG) asociado a implantes de mama en Españahttps://www.pharmaradar360.com/article/c438fa90b018061aPharma Surgeen2026-06-03T11:55:54.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/a0c5eef0e5dead4cPharma Surgeen2026-06-03T11:45:00.000ZAfter empty promises, string theory finds new useshttps://www.pharmaradar360.com/article/c225458579433105Pharma Surgeen2026-06-03T11:44:37.000ZGreetings from bi-annual CBRU seminarhttps://www.pharmaradar360.com/article/f0461ff50cc6aa6dPharma Surgeen2026-06-03T11:21:00.000ZAHA lays out blueprint to improve affordability, care access and qualityhttps://www.pharmaradar360.com/article/fad94d0642a308baPharma Surgeen2026-06-03T11:17:31.000ZJornada por el día mundial del ambiente: acción por el clima, del saber al hacerhttps://www.pharmaradar360.com/article/f8bb6e7b2b81f565Pharma Surgeen2026-06-03T11:13:00.000ZOrgullo: María Delfina Sciutto se graduó con honores en Derecho y fue premiada por la Corte Supremahttps://www.pharmaradar360.com/article/981cdac628735f0bPharma Surgeen2026-06-03T11:12:25.000ZAUGM DOMUS en el Latindex y se consolida como revista científica de referencia regionalhttps://www.pharmaradar360.com/article/58ab75718e0a7e7cPharma Surgeen2026-06-03T11:11:27.000ZJornada por una Universidad libre de humo y nicotinahttps://www.pharmaradar360.com/article/caaec9d38cb6c633Pharma Surgeen2026-06-03T11:10:50.000ZEl Tren Universitario cumple 13 años de servicio: un motor que transformó la movilidad de la regiónhttps://www.pharmaradar360.com/article/d09308d7df524923Pharma Surgeen2026-06-03T11:05:00.000ZMedtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United Stateshttps://www.pharmaradar360.com/article/69f89d626d847febPharma Surgeen2026-06-03T10:56:54.000ZMagdalena Held will defend her PhD thesishttps://www.pharmaradar360.com/article/55cffcffda0b58f9Pharma Surgeen2026-06-03T10:55:00.000ZMedtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadenshttps://www.pharmaradar360.com/article/178298151e75868cPharma Surgeen2026-06-03T10:47:55.000ZRezolute’s stock up on interim Phase III tumour HI datahttps://www.pharmaradar360.com/article/7f92b11714342011Pharma Surgeen2026-06-03T10:45:00.000ZMedtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 yearshttps://www.pharmaradar360.com/article/d314e3b8fe1b604bPharma Surgeen2026-06-03T10:44:00.000ZAmid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in UShttps://www.pharmaradar360.com/article/a861a6ff5a33b815Pharma Surgeen2026-06-03T10:09:32.000ZGilead eyes PBC expansion for Livdelzi on positive one-year datahttps://www.pharmaradar360.com/article/d0129876d6569fb3Pharma Surgeen2026-06-03T10:07:00.000ZUnlocking Unstructured Data with AI for Optimized Protocol Developmenthttps://www.pharmaradar360.com/article/98be2bb182334a0ePharma Surgeen2026-06-03T10:04:27.000ZContraline secures $92.5m to push male contraceptive into late-stage trialshttps://www.pharmaradar360.com/article/5dd01edd5e5869b8Pharma Surgeen2026-06-03T10:00:00.000ZModernizing Market Access and Patient Support Services: Q&A with Cam Olighttps://www.pharmaradar360.com/article/f1a38c07b0346cfaPharma Surgeen2026-06-03T09:54:00.000ZWith Cencora pact, Gilead looks to grow CAR-T treatment center networkhttps://www.pharmaradar360.com/article/b5692606330c155dPharma Surgeen2026-06-03T09:53:11.000ZInipharm commences dosing in INI-822 trial for MASHhttps://www.pharmaradar360.com/article/63217180d92a31f1Pharma Surgeen2026-06-03T09:51:00.000ZThe watchdog overseeing the integrity of HHS programshttps://www.pharmaradar360.com/article/42c9cab466df5b73Pharma Surgeen2026-06-03T09:36:51.000ZAbbVie receives EC approval for Aquipta to treat migrainehttps://www.pharmaradar360.com/article/e558bfdea0653ca9Pharma Surgeen2026-06-03T09:32:00.000ZRegeneron pays $37M, adds $2B in biobucks to expand CytomX pacthttps://www.pharmaradar360.com/article/6d822f08498ffdbbPharma Surgeen2026-06-03T09:30:00.000ZCoffee, racetracks, beaches and more coffee—inside the ASCO 2026 exhibit floorhttps://www.pharmaradar360.com/article/51547deb486afaa2Pharma Surgeen2026-06-03T09:14:16.000ZContactpunt afdeling Geneesmiddelen voor Diergeneeskundig Gebruikhttps://www.pharmaradar360.com/article/10bf3f279286b5e0Pharma Surgeen2026-06-03T09:00:07.000ZBiDil — The Story of the Black Pillhttps://www.pharmaradar360.com/article/1a9865dd190f91e5Pharma Surgeen2026-06-03T09:00:07.000ZKidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapyhttps://www.pharmaradar360.com/article/3d8f2f219a9b37cePharma Surgeen2026-06-03T09:00:07.000ZAll-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemiahttps://www.pharmaradar360.com/article/dcb30a3460e14fb2Pharma Surgeen2026-06-03T09:00:07.000ZChyluria from a Lymphatic–Urinary Fistulahttps://www.pharmaradar360.com/article/16f9973503012997Pharma Surgeen2026-06-03T09:00:07.000ZThe Unusual Suspectshttps://www.pharmaradar360.com/article/91b4501c81e0b38fPharma Surgeen2026-06-03T09:00:07.000ZVirtual-Only or In-Person Interviews for Residency Applicantshttps://www.pharmaradar360.com/article/aebceac0d5b267f0Pharma Surgeen2026-06-03T09:00:07.000ZFasting, Glucocorticoids, and Breast Cancerhttps://www.pharmaradar360.com/article/57194b62659ca0adPharma Surgeen2026-06-03T09:00:07.000ZChronic Myeloid Leukemia in Low- and Middle-Income Countrieshttps://www.pharmaradar360.com/article/d227afaff6736e40Pharma Surgeen2026-06-03T09:00:07.000ZRomiplostim versus Placebo for Chemotherapy-Induced Thrombocytopeniahttps://www.pharmaradar360.com/article/e810a7abbf9c07f9Pharma Surgeen2026-06-03T09:00:07.000ZPolymyalgia Rheumaticahttps://www.pharmaradar360.com/article/c338bd303770acc8Pharma Surgeen2026-06-03T09:00:07.000ZFinerenone in Type 1 Diabetes and Chronic Kidney Diseasehttps://www.pharmaradar360.com/article/a861c78c6381aef8Pharma Surgeen2026-06-03T09:00:07.000ZTargeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastomahttps://www.pharmaradar360.com/article/32ab33620c537085Pharma Surgeen2026-06-03T09:00:07.000ZKidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cellshttps://www.pharmaradar360.com/article/eaa39d9d986f4770Pharma Surgeen2026-06-03T08:55:30.000ZTrust’s urgent and emergency care services maintain ‘outstanding’ and ‘good’ ratings from CQChttps://www.pharmaradar360.com/article/9a7f978e10db82caPharma Surgeen2026-06-03T08:48:02.000ZMoonlight begins SURVEYOR Phase I trial for peanut allergyhttps://www.pharmaradar360.com/article/bd449a35f9785843Pharma Surgeen2026-06-03T08:46:09.000ZRoche’s giredestrant secures FDA priority review for breast cancerhttps://www.pharmaradar360.com/article/b1acafdb42ee3478Pharma Surgeen2026-06-03T08:40:00.000ZTicket sale for Eurekaweek 2026 has startedhttps://www.pharmaradar360.com/article/e9808c676559cd46Pharma Surgeen2026-06-03T08:19:34.000ZChoosing the hardest problems: why Ipsen focuses where unmet need is greatesthttps://www.pharmaradar360.com/article/aeb524555a497514Pharma Surgeen2026-06-03T08:16:59.000ZUniversité Paris Cité Joins Landmark UK-France Alliance in Health Researchhttps://www.pharmaradar360.com/article/c839330fdb4eadc4Pharma Surgeen2026-06-03T08:10:07.000ZHSSH May Newsletter 5/2026https://www.pharmaradar360.com/article/9f81f1d46464900cPharma Surgeen2026-06-03T08:05:34.000ZNIH scientists criminally charged for bringing monkeypox virus into US, although samples ‘inactivated’https://www.pharmaradar360.com/article/30ee6b23afc4be77Pharma Surgeen2026-06-03T08:04:05.000Zレギュラトリーサイエンス戦略相談に関する実施要綱の一部改正について（医薬品医療機器総合機構）https://www.pharmaradar360.com/article/3d4f084669b88209Pharma Surgeen2026-06-03T08:03:29.000ZSurge in M&As driven by patent expirationshttps://www.pharmaradar360.com/article/59a2a6536241bddcPharma Surgeen2026-06-03T07:59:08.000ZBewegung verändert Leben – vom Patienten zum Spitzensportlerhttps://www.pharmaradar360.com/article/811377b98e94db02Pharma Surgeen2026-06-03T07:53:17.000ZCALL FOR PAPERS: Governing and Navigating Everyday Life – Interdisciplinary Perspectives on Sex Work and Commercial Sexhttps://www.pharmaradar360.com/article/d8241ebfbcc30f06Pharma Surgeen2026-06-03T07:29:21.000Z‘Cancer crisis’: Experts warn of impending global shortage of radiology professionalshttps://www.pharmaradar360.com/article/2d90f2bef1cd5595Pharma Surgeen2026-06-03T07:27:36.000ZSamtalsgrupper ska skapa trygghet för patienter med könsdysforihttps://www.pharmaradar360.com/article/f5719e19de581729Pharma Surgeen2026-06-03T07:24:48.000ZDoctoral Dissertation: Urban environmental choices shape the microbial community and may affect healthhttps://www.pharmaradar360.com/article/b51fb3110f430aafPharma Surgeen2026-06-03T07:23:00.000Zbio:cap bringt internationale Life-Sciences-, KI- und Investment-Entscheider nach Berlinhttps://www.pharmaradar360.com/article/f0639a617a7549e6Pharma Surgeen2026-06-03T07:20:21.000ZInternational medical graduates represent nearly 25% of diagnostic radiologists in UShttps://www.pharmaradar360.com/article/3d627b255c578cd6Pharma Surgeen2026-06-03T07:19:26.000Z第32回東北大学病院緩和ケア地域連携カンファレンス開催のお知らせ（7/24開催）https://www.pharmaradar360.com/article/e2943c2412e4e073Pharma Surgeen2026-06-03T07:18:19.000ZWe are EMBL: Neeya Jacob on streamlining operations and preserving the spark of her inner childhttps://www.pharmaradar360.com/article/f6430cb8fe6931b7Pharma Surgeen2026-06-03T07:06:07.000ZLumexa Imaging inks new joint venture with Hospital for Special Surgeryhttps://www.pharmaradar360.com/article/a8886f313a2aa61dPharma Surgeen2026-06-03T07:05:57.000ZPeople in Rotterdam haven’t ‘dropped out’, but have good reasons for avoiding the newshttps://www.pharmaradar360.com/article/3a042834d5ce5776Pharma Surgeen2026-06-03T07:04:37.000Z【日本肺癌学会】第40回日本肺癌学会ワークショップ［7月18日（土）開催］https://www.pharmaradar360.com/article/10dd73c675191c1bPharma Surgeen2026-06-03T07:00:00.000Z‘EDGE in Action’ highlights district’s innovation taking shapehttps://www.pharmaradar360.com/article/2b90831a7cf19d01Pharma Surgeen2026-06-03T07:00:00.000ZHiding in plain sighthttps://www.pharmaradar360.com/article/e4f86ea19d7373d2Pharma Surgeen2026-06-03T07:00:00.000ZNeutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target receptor binding siteshttps://www.pharmaradar360.com/article/f688fbd43ee13dc8Pharma Surgeen2026-06-03T07:00:00.000ZHIV-1 infection converts CD4+ T cells to HLA class II–restricted CD8+ T cellshttps://www.pharmaradar360.com/article/6400ef72365293b8Pharma Surgeen2026-06-03T07:00:00.000ZCryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunctionhttps://www.pharmaradar360.com/article/3bad7914b5bdbd09Pharma Surgeen2026-06-03T07:00:00.000ZReprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical modelshttps://www.pharmaradar360.com/article/7fa58c7a2cdfdc7ePharma Surgeen2026-06-03T07:00:00.000ZToll-like receptor 5 protects against murine lung fibrosis through reduced dysbiosis, and TLR5 deficiency is associated with human IPFhttps://www.pharmaradar360.com/article/b6cc8b6d07fd6b22Pharma Surgeen2026-06-03T07:00:00.000ZClaudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelshttps://www.pharmaradar360.com/article/a532707cf4e4ff61Pharma Surgeen2026-06-03T07:00:00.000Z#DONAZIONEORGANI Elisabetta e Francesco, una lezione sul tempo “Futuro”https://www.pharmaradar360.com/article/2d28f242f90b3fcdPharma Surgeen2026-06-03T07:00:00.000ZNHSGGC burn centre to host international conference as national profile growshttps://www.pharmaradar360.com/article/751c26f61970a5c3Pharma Surgeen2026-06-03T07:00:00.000ZTwo-thirds of the most severe patients with anti-NMDAR encephalitis recoverhttps://www.pharmaradar360.com/article/ca285c3461abaa4fPharma Surgeen2026-06-03T07:00:00.000ZStroke in young adults: why it is increasingly affecting those under 55https://www.pharmaradar360.com/article/79e8c9b2742ec2e3Pharma Surgeen2026-06-03T07:00:00.000ZAir pollution may be harming your brain’s ‘encyclopedia’https://www.pharmaradar360.com/article/9e03ee85ad4d0b33Pharma Surgeen2026-06-03T06:58:00.000ZDr. Davies visiting Scottsbluff for priority candidate forumshttps://www.pharmaradar360.com/article/d7cd7dd5f7778003Pharma Surgeen2026-06-03T06:56:00.000ZUniversity of Nebraska Foundation: 90 years of impacthttps://www.pharmaradar360.com/article/3abcd10bf2bedea0Pharma Surgeen2026-06-03T06:54:00.000ZA new era for lab workflows at the med centerhttps://www.pharmaradar360.com/article/3e0dc7605c9c9318Pharma Surgeen2026-06-03T06:53:15.000ZFour SU finalists in running for SA’s prestigious ‘Science Oscars’https://www.pharmaradar360.com/article/a6a924080b8a6fc9Pharma Surgeen2026-06-03T06:47:00.000ZA patient-first shift in disease language and communicationhttps://www.pharmaradar360.com/article/fefd44ba929ffac3Pharma Surgeen2026-06-03T06:30:38.000ZNHS AI scribe rollout should include national oversight, report findshttps://www.pharmaradar360.com/article/0bc9dc2d4e927cd0Pharma Surgeen2026-06-03T06:14:01.000ZScientists discovered something surprising about french fries and diabeteshttps://www.pharmaradar360.com/article/783c6a89b77ca8fcPharma Surgeen2026-06-03T05:34:30.000ZMiikka Laitinen’s doctoral defence 12.6.2026https://www.pharmaradar360.com/article/fa73942c340d5853Pharma Surgeen2026-06-03T05:01:06.000ZTrends from the Trenches: AI-Ready Life Sciences Datahttps://www.pharmaradar360.com/article/24eccf2e91b416d4Pharma Surgeen2026-06-03T04:50:00.000ZPharmaceutical Logistics: Finding Shipping Solutions that Match Your Level of Precision and Care (May 2026)https://www.pharmaradar360.com/article/39c0568f73d978f2Pharma Surgeen2026-06-03T04:50:00.000ZPharmaceutical Cold-Chain Logistics: Protecting Integrity from End to End (May 2026)https://www.pharmaradar360.com/article/60e6f8651a172806Pharma Surgeen2026-06-03T04:50:00.000ZBeyond the Dashboard: Why Certification is the New Currency in Pharma Logisticshttps://www.pharmaradar360.com/article/c91aec60c9da832bPharma Surgeen2026-06-03T04:46:00.000ZBrain scans reveal two distinct types of autismhttps://www.pharmaradar360.com/article/2592c1ceff24d6a0Pharma Surgeen2026-06-03T04:26:00.000ZFDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emailshttps://www.pharmaradar360.com/article/4c80b6fb88c84b2dPharma Surgeen2026-06-03T04:00:00.000Z#VOLONTARIATO [22.06] Cieli Azzurri, concerto jazz per i bambini del Policlinico di Milanohttps://www.pharmaradar360.com/article/76cfb621f275fc1dPharma Surgeen2026-06-03T02:59:00.000ZIMU Biosciences nabs $53M funding round to ‘decode’ the immune systemhttps://www.pharmaradar360.com/article/29a1d7bf86c08c41Pharma Surgeen2026-06-03T01:46:46.000ZFDA Issues Final Guidance for Content of Human Factors Information in Medical Device Submissionshttps://www.pharmaradar360.com/article/a2ddcd3bd4fd87d2Pharma Surgeen2026-06-03T01:40:00.000ZNeurotech launches new YouTube channel to spotlight patients’ stories for rare eye disorderhttps://www.pharmaradar360.com/article/3f368a3009cdccffPharma Surgeen2026-06-03T01:30:46.000Z3学会合同ゲノム医療推進タスクフォース『次世代シークエンサー等を⽤いた遺伝⼦パネル検査に基づく固形がん診療に関するブリーフィングレポート』についてhttps://www.pharmaradar360.com/article/7d7820249b5408b4Pharma Surgeen2026-06-03T01:14:33.000Z第12回 AYAカフェ-AYA世代のためのがん患者カフェ-開催のお知らせ（7/12開催）https://www.pharmaradar360.com/article/721e81808d5e3bb7Pharma Surgeen2026-06-03T01:04:16.000ZFacultades de campus San Joaquín dialogaron sobre el Plan Estratégico UC desde las humanidadeshttps://www.pharmaradar360.com/article/cd05e4e21d8e8a50Pharma Surgeen2026-06-03T00:04:44.000ZFlinders research leader recognised as outstanding educatorhttps://www.pharmaradar360.com/article/1f53e61a1914c335Pharma Surgeen2026-06-03T00:00:00.000ZTumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomahttps://www.pharmaradar360.com/article/6aa0d65844ed5de3Pharma Surgeen2026-06-03T00:00:00.000ZMachine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugshttps://www.pharmaradar360.com/article/ad59d278c46399a1Pharma Surgeen2026-06-03T00:00:00.000ZSingle-cell multi-omic atlas and morphogen screening informs midbrain and hindbrain organoid engineeringhttps://www.pharmaradar360.com/article/150171f9abcffe3ePharma Surgeen2026-06-03T00:00:00.000ZThe representational geometry of emotional states in basolateral amygdalahttps://www.pharmaradar360.com/article/60ec8b3ee44b71ffPharma Surgeen2026-06-03T00:00:00.000ZA brainstem pathway underlying vagal modulation of somatic pain and affective stateshttps://www.pharmaradar360.com/article/ae93d79e441aec92Pharma Surgeen2026-06-03T00:00:00.000ZLimited evidence of AI superiority in seasonal influenza vaccine strain selectionhttps://www.pharmaradar360.com/article/d2cf35c6b5afec05Pharma Surgeen2026-06-03T00:00:00.000ZReply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selectionhttps://www.pharmaradar360.com/article/6e3a87322fc40cd6Pharma Surgeen2026-06-03T00:00:00.000ZReinventing biotech systems for patient impacthttps://www.pharmaradar360.com/article/bafca617b10e641fPharma Surgeen2026-06-03T00:00:00.000ZAssessing quality of childbirth care provided by skilled health personnel in Exemplar countrieshttps://www.pharmaradar360.com/article/334d6ad3160fcf18Pharma Surgeen2026-06-03T00:00:00.000ZProgrammable control of bacterial operons with a single Cas13 RNA effectorhttps://www.pharmaradar360.com/article/2ad93690712cb3a4Pharma Surgeen2026-06-03T00:00:00.000ZSingle-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumorshttps://www.pharmaradar360.com/article/5dd1fc8dcb811845Pharma Surgeen2026-06-03T00:00:00.000ZEditorial Expression of Concern: Functional proteomic identification of DNA replication proteins by induced proteolysis in vivohttps://www.pharmaradar360.com/article/5b98102c34123a27Pharma Surgeen2026-06-03T00:00:00.000ZChiral superfluorescence from perovskite superlattices at room temperaturehttps://www.pharmaradar360.com/article/db829895089d9fa8Pharma Surgeen2026-06-03T00:00:00.000ZCell-type-resolved genetic variation shapes inflammatory bowel disease riskhttps://www.pharmaradar360.com/article/274de2ff6ab4092bPharma Surgeen2026-06-03T00:00:00.000ZEarth’s east–west albedo symmetryhttps://www.pharmaradar360.com/article/d37f8266030edb7dPharma Surgeen2026-06-03T00:00:00.000ZAcquired genetic and cell-state changes in IDH-mutant glioma progressionhttps://www.pharmaradar360.com/article/a7d6a637cec960bePharma Surgeen2026-06-03T00:00:00.000ZPlastoglobules compartmentalize nitrogen assimilation in maizehttps://www.pharmaradar360.com/article/91ebffcab417b06ePharma Surgeen2026-06-03T00:00:00.000ZAnalysis of trade-offs of post-sorting plastic packaginghttps://www.pharmaradar360.com/article/ed57ad02c97969f9Pharma Surgeen2026-06-03T00:00:00.000ZCold-induced peptide signalling secures pollen resilience and crop yield